Tovkai O A, Palamarchuk V O, Shidlovskyi O V, Shidlovskyi V O, Kuts V V, Smoliar V A, Sheremet M I, Levchuk R D, Morozovych I I, Cretoiu D, Lazaruk O V
Ukrainian Scientific and Practical Center of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues, Ministry of Health of Ukraine, Kyiv, Ukraine.
"I. Horbachevsky" Ternopil National Medical University, Ministry of Education of Ukraine, Ternopil, Ukraine.
Acta Endocrinol (Buchar). 2023 Jan-Mar;19(1):142-146. doi: 10.4183/aeb.2023.142. Epub 2023 Aug 14.
To determine the effectiveness of the basal calcitonin (CTb) determination in the early postoperative period to predict the possible recurrence (persistence) of medullary thyroid cancer (MTC).
A retrospective study of the treatment results in 194 patients with MTC (148 (76.3%) primary - group 1 and 46 (23.8%) recurrent - group 2) according to the levels of CTb in the first week after surgery and one year later. All groups were analyzed by staging, the level of preoperative and postoperative basal calcitonin 5 days and 1 year after the primary surgery.
Among all patients, women prevailed - 144 (74.2%), the average age was (48.7±15.2), the average follow-up period was 67.5 months. Basal calcitonin was studied in patients of all groups in the preoperative and serially in the postoperative periods: 5 days and 1 year after the most radical surgical volumes. To test the hypothesis about the possibility of using CTb indicators in the early postoperative period, the degree of compliance with normal calcitonin indicators (≤18 pg/mL) was assessed by observation groups 5 days and 1 year after surgery.
确定术后早期基础降钙素(CTb)测定对预测甲状腺髓样癌(MTC)可能复发(持续存在)的有效性。
一项回顾性研究,根据术后第一周及一年后的CTb水平,分析194例MTC患者(148例(76.3%)为原发性——第1组,46例(23.8%)为复发性——第2组)的治疗结果。所有组均按分期、初次手术后5天及1年的术前和术后基础降钙素水平进行分析。
在所有患者中,女性占多数——144例(74.2%),平均年龄为(48.7±15.2)岁,平均随访期为67.5个月。对所有组患者在术前及术后连续进行基础降钙素研究:在进行最彻底手术量后的5天及1年。为检验术后早期使用CTb指标可能性的假设,通过观察组在术后5天及1年评估降钙素指标符合正常水平(≤18 pg/mL)的程度。